Patients must have histologically or cytologically documented adenocarcinoma of the colon or rectum that is metastatic or locally advanced and unresectable
Histologically or cytologically confirmed diagnosis of selected locally advanced or metastatic solid tumors
Diagnosed with histologically or cytologically confirmed locally advanced/metastatic NSCLC with EGFR mutation
Histologically or cytologically documented locally advanced or metastatic urothelial carcinoma
Histologically or cytologically confirmed adenocarcinoma of the breast with unresectable locally advanced disease, or metastatic disease and HER2 IHC 1+ or 2+ OR
Histologically or cytologically confirmed adenocarcinoma of the breast with unresectable locally advanced disease, or metastatic disease and HER2 IHC 3+ or positive for HER2 gene amplification
Histologically or cytologically confirmed locally advanced or metastatic gastric cancer and HER2 IHC 3+ or positive for HER2 gene amplification OR
Patients who have the below specified histologically or cytologically confirmed malignancies that have progressed to the advanced or metastatic stage.
Has histologically or cytologically confirmed metastatic, or unresectable locally advanced, recurrent NSCLC.
Histologically or cytologically confirmed locally advanced or metastatic Triple Negative Breast Cancer.
Histologically or cytologically confirmed diagnosis of locally advanced or metastatic ALK-positive NSCLC; at least 1 extracranial measurable target lesion not previously irradiated. CNS metastases allowed if asymptomatic and not currently requiring corticosteroid treatment.
Patients must have histologically or cytologically documented carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder with clinical and/or radiologic evidence of unresectable, locally advanced or metastatic disease; patients with ampullary carcinoma are not eligible
Must have immune checkpoint naïve histologically/cytologically confirmed advanced or metastatic CRC.
Patients must have histologically or cytologically confirmed advanced or metastatic:
Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; patients with documented lymphomas.
Have histologically or cytologically-documented diagnosis of advanced (metastatic and/or unresectable) thymic carcinoma, for which no curative treatment (including surgery, radiation, or other) is available
Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; patients with documented lymphomas.
Histologically- or cytologically- confirmed locally advanced or metastatic nonfunctional well differentiated neuroendocrine tumor (WDNET)
Patients must have histologically or cytologically confirmed, inoperable or unresectable locally advanced, or metastatic NSCLC
Histologically or cytologically confirmed metastatic or unresectable locally advanced, non-squamous, NSCLC
Histologically or cytologically confirmed diagnosis of metastatic or unresectable, locally advanced, recurrent NSCLC that has been previously treated (subjects who have failed adjuvant or locally advanced therapy within 6 months are also eligible to participate in the study)
Patients must have histologically or cytologically confirmed invasive breast cancer, which is recurrent, locally advanced, unresectable or metastatic
Histologically or cytologically confirmed metastatic or locally advanced adenocarcinoma of the pancreas
Histologically or cytologically documented locally advanced, inoperable or metastatic solid tumors with documented AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations
Patients must have histologically or cytologically documented carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder with clinical and/or radiologic evidence of unresectable, locally advanced or metastatic disease; patients with ampullary carcinoma are not eligible
Patients with histologically or cytologically-confirmed, locally advanced, or metastatic solid malignancy that is relapsed, refractory, or progressing following at least 1 prior systemic therapy (Part A)
Patients in Part B must have histologically or cytologically-confirmed, locally-advanced, or metastatic solid malignancy within the disease indications of Part A
Histologically or cytologically confirmed locally advanced, inoperable, or metastatic tumors: • Carboplatin Plus Paclitaxel Arm:
Patients with histologically documented locally advanced, recurrent and/or metastatic NSCLC
For dose escalation cohort: patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors who have failed at least one line of therapy
Arm 2: histologically or cytologically confirmed adenocarcinoma of the pancreas that is locally advanced or metastatic
Histologically or cytologically documented, incurable, unresectable locally advanced, or metastatic breast cancer
Phase II: Patients must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast
Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable tumors
Histologically or cytologically documented disease
Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; patients with documented lymphomas.
Histologically or cytologically confirmed advanced (unresectable and/or metastatic) HCC
Part 1: Has a histologically- or cytologically-documented, locally-advanced or metastatic solid malignancy and has received ?1 and <6 prior line of cancer treatment regimen(s).
Histologically or cytologically proven metastatic or locally advanced disease. Specifically:
Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma with locally advanced or metastatic disease
Patients must have histologically or cytologically confirmed advanced leiomyosarcoma of the uterus (ULMS); advanced ULMS is defined as metastatic ULMS or unresectable primary ULMS
-  Histologically or cytologically confirmed metastatic or unresectable locally advanced\n             NSCLC
Patients must have histologically or cytologically confirmed metastatic or unresectable locally advanced adenocarcinoma of the pancreas with no prior systemic therapy for metastatic or locally advanced disease
Histologically or cytologically confirmed diagnosis of relapsed or refractory advanced or metastatic malignancies:
Has histologically- or cytologically-confirmed diagnosis of locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma
Histologically or cytologically documented, locally advanced or metastatic NSCLC.
Postmenopausal women with histologically or cytologically confirmed locally advanced or metastatic ER positive breast cancer
Patients must have histologically or cytologically documented adenocarcinoma of the colon or rectum that is either metastatic, or locally advanced and unresectable; NOTE: in the event that both cecal and appendiceal primaries are considered, patient is eligible if it is concluded by the treating oncologist to most likely be cecal based on pathological, surgical, and clinical interpretation
Females 18 years old and greater with histologically or cytologically confirmed diagnosis of advanced or metastatic adenocarcinoma of the breast.
Subjects with cytologically or histologically confirmed locally advanced or metastatic solid tumor malignancy
Histologically or cytologically confirmed locally advanced or metastatic colon or rectal adenocarcinoma
Cytologically or histologically confirmed adenocarcinoma of locally advanced or metastatic NSCLC which is not amenable to curative surgery or radiotherapy
Patients must have histologically or cytologically documented carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder with clinical and/or radiologic evidence of unresectable, locally advanced or metastatic disease; patients with ampullary carcinoma are not eligible
Patients must have histologically or cytologically confirmed advanced or metastatic cancer for which capecitabine treatment is considered a standard treatment option
Histologically or cytologically confirmed metastatic or recurrent NSCLC; primary or metastatic site may be used for histology
Phase Ib: Patients must have histologically or cytologically confirmed locally advanced renal cell carcinoma
Histologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic.
Participants must have histologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma
Patients with cytologically or histologically confirmed recurrent locally advanced or metastatic NSCLC have received at least one prior recognized systemic therapy for therapy for advanced disease, (recognized therapy must include a platinum doublet unless contraindicated due to organ dysfunction)
Histologically or cytologically proven diagnosis of unresectable B3 thymoma or thymic carcinoma recurrent or progressing after more than one prior systemic therapy for advanced / metastatic disease
Histologically or cytologically confirmed diagnosis of metastatic or unresectable, locally advanced, recurrent NSCLC that has been previously treated (subjects who have failed adjuvant or locally advanced therapy within 6 months are also eligible to participate in the study)
Has histologically- or cytologically-confirmed diagnosis of locally advanced unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the esophagogastric junction (EGJ)
Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent:
Histologically or cytologically proved diagnosis of locally advanced recurrent or metastatic non-squamous NSCLC that is not suitable for local curative treatment.
Histologically or cytologically confirmed metastatic or unresectable locally advanced/metastatic NSCLC
Subject has definitive histologically or cytologically confirmed locally advanced unresectable or metastatic pancreatic adenocarcinoma (islet cell neoplasms are excluded) that is measurable by RECIST Version 1.1 guidelines.
Patients with a histologically/cytologically confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors:
Histologically or cytologically confirmed locally advanced or metastatic urothelial carcinoma (UC)
Histologically or cytologically confirmed metastatic or unresectable locally advanced NSCLC with EGFR activating mutation (excluding exon 20 insertion); measurable disease per RECIST 1.1
Histologically or cytologically documented unresectable, locally advanced or metastatic breast cancer or gastric cancer refractory to standard therapy.
Cytologically or histologically confirmed advanced gastric or GEJ adenocarcinoma that is metastatic or locally advanced and unresectable.
Histologically or cytologically confirmed advanced/metastatic SCLC or NSCLC
Patients with a documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic.
For paclitaxel combination arms: histologically or cytologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease
For docetaxel combination arms: histologically or cytologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease or histologically documented advanced (Stage IV) or recurrent NSCLC
Patients with a documented (histologically- or cytologically-proven) epithelial cell/adenocarcinoma of the pancreas that is relapsed, locally advanced, or metastatic.
Histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally advanced disease not amenable to curative resection
Histologically or cytologically confirmed, locally advanced or metastatic squamous NSCLC
Subject has histologically or cytologically confirmed metastatic or locally advanced, unresectable solid tumors harboring EGFR mutations.
Histologically or cytologically confirmed locally advanced or metastatic adenocarcinoma of the stomach or GEJ in participants who have not received prior systemic therapy for metastatic disease
Histologically or cytologically confirmed locally mEC or metastatic adenocarcinoma of the GEJ Siewert Classification Type I in participants who have not received prior systemic therapy for primary and metastatic disease or chemoradiation therapy for primary disease
Subject has histologically or cytologically documented diagnosis of pancreatic adenocarcinoma with metastatic disease. Locally advanced subjects are not eligible.
Patients must have histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease.
